Zacks Investment Research | Jun 29, 2016 02:23AM ET
Gilead (NASDAQ:GILD) once again showed its expertise in the hepatitis C virus (HCV) segment by gaining FDA approval for yet another drug, Epclusa. However, another company, Regulus (NASDAQ:RGLS) suffered a setback related to its experimental HCV treatment.
Recap of the Week’s Most Important Stories
1. Gilead got some good news for both its key franchises – HIV and HCV. The company gained European approval for its HIV treatment, Odefsey, the second single tablet regimen containing the Descovy backbone and the third product in the company’s new TAF portfolio to gain approval in Europe (Read more: MEDICAL-BIOMED/GENETICS Industry Price Index
Among major biotech stocks, Gilead gained 0.6% over the last five trading days while Alexion (NASDAQ:ALXN) was impacted by the Brexit sell-off with shares declining 7.4%. Over the last six months, Alexion lost 39.2%.
What's Next in the Biotech World?
Watch out for the usual pipeline updates and data presentations from biotech companies.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.